查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1362919

血红素病市场规模、份额、趋势分析报告：按类型、诊断、治疗、区域、细分趋势，2023-2030

Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), By Diagnosis, By Therapy, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

血红蛋白病市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球血红素病市场规模预计将达到207亿美元，2023年至2030年年复合成长率为12.6%。

由于镰状细胞疾病（SCD）和地中海贫血等疾病的患病不断增加，该市场正在稳步增长。促进因素包括诊断技术的进步、意识的提高和医疗基础设施的改善。此外，创新治疗方法的发展和政府配合措施也有助于市场扩张。

近年来，镰状细胞疾病的诊断技术有了显着进展。一个显着的趋势是越来越多地使用分子遗传学检测，特别是 DNA 分析，来鉴定与镰状细胞疾病相关的特定突变。这种方法可以进行精确和准确的诊断，使医疗专业人员能够确定个体是否存在镰状细胞性状或 SCD。此外，技术进步促进了即时检查装置的发展，可以在资源有限的环境中进行快速筛选和诊断。诊断技术的这些进步不仅有利于早期发现和早期疗育，而且有利于那些有遗传性镰状细胞疾病风险的人的遗传咨询和计划生育。

近年来，血红蛋白疾病（包括 SCD 和地中海贫血）的治疗进展显示出有希望的趋势。基因治疗方法的开发和利用是市场的普遍普及之一。基因疗法旨在透过将功能基因引入罹患的细胞来纠正导致这些疾病的基因突变。多项成功的临床试验表明，疾病症状显着改善，患者输血依赖性降低。此外，CRISPR-Cas9等基因编辑技术的出现具有精确纠正患者自身细胞内缺陷基因的巨大潜力。这种创新方法在临床前研究中显示出有希望的结果，并可能在不久的将来为血红蛋白疾病提供一种根治性选择。此外，支持治疗的进步，例如输血方案、铁螯合疗法和干细胞移植技术的改进，继续有助于改善血红蛋白疾病患者的预后。

增加用于开发治疗血红蛋白病的新治疗方法的投资和资金筹措预计将在预测期内进一步推动市场成长。例如，2023 年 5 月，美国参议员提出了 Sickle 法案，该法案将为改善越来越多镰状细胞疾病患者的生活品质的服务提供资金，并为治疗镰状细胞疾病的医务人员提供支持。我们已提交了Cell护理扩展法。此外，布朗克斯血液研究基金会 (BBRF) 等私人资金为地中海贫血和其他血红蛋白疾病的研究和管理提供了基础。

治疗成本急剧上升可能会对市场产生负面影响。例如，美国美国卫生研究院的一项新研究表明，64 岁以下患有镰状细胞疾病的美国人在一生中患镰状细胞疾病的几率比没有镰状细胞疾病的人要低。这些医疗费用大约多出44,000 美元。此外，保险公司平均为每位镰状细胞疾病患者支付 170 万美元。

血红蛋白病市场报告亮点

  • 在2022年的血红蛋白疾病市场中，镰状细胞疾病细分市场占据最大份额，达到58.6%，预计在预测期内将以最快的速度成长。这是由生物製药公司和非营利组织越来越多致力于改善镰状细胞疾病治疗机会的倡议所推动的。
  • 由于北美和欧洲的高诊断率，镰状细胞诊断领域在血红蛋白疾病市场占据主导地位，到2022年将占50.5%的份额。
  • 依治疗方法划分，镰状细胞疾病领域占最大销售份额，2022年为62.1%。广泛的研究加上政府资助开发治疗镰状细胞疾病的新治疗方法是促进该领域发展的主要要素。
  • 收益占有率%。
  • 预计亚太地区在预测期内将呈现最快的成长率。镰状细胞疾病和地中海贫血罹患的高盛行率预计将推动未来年度的市场成长。

目录

第1章调查方法与范围

第2章执行摘要

第3章市场变数、趋势和范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL分析
    • 新型冠状病毒感染疾病（COVID-19）影响分析

第4章业务分析的类型

  • 血红素病市场：类型变异分析
  • 地中海型贫血
  • 镰状细胞疾病
  • 血红素变异体

第5章诊断业务分析

  • 血红素病市场：诊断波动分析
  • 地中海型贫血
  • 镰状细胞疾病
  • 血红素变异体

第6章治疗业务分析

  • 血红素病市场：治疗变异分析
  • 地中海型贫血
  • 镰状细胞疾病
  • 血红素变异体

第7章区域业务分析

  • 2022 年和 2030 年按地区分類的血红素病市场占有率
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第8章竞争形势

  • 参与企业
    • Sangamo Therapeutics
    • Bluebird bio, Inc.
    • Global Blood Therapeutics, Inc
    • Pfizer, Inc.
    • Emmaus Life Sciences, Inc.
    • Prolong Pharmaceuticals, LLC
    • Celgene Corporation (BMS)
    • Bioverativ, Inc. (Sanofi)
    • Gamida Cell
    • Novartis AG
  • 参与企业概况
  • 财务实绩
  • 产品基准评效
  • 2022 年公司市场占有率分析
  • 策略规划

第9章分析师的观点

Product Code: 978-1-68038-736-0

Hemoglobinopathies Market Growth & Trends:

The global hemoglobinopathies market size is expected to reach USD 20.70 billion by 2030 and is expected to expand at a CAGR of 12.6% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market is experiencing steady growth due to increasing prevalence of disorders like sickle cell disease (SCD) and thalassemia. The driving factors include advancements in diagnostic techniques, growing awareness, and improving healthcare infrastructure. Additionally, the development of innovative therapies and government initiatives are contributing to market expansion.

In recent years, there have been significant advancements in diagnostic techniques for sickle cell disease. One prominent trend is the increased utilization of molecular genetic testing, specifically DNA analysis, to identify specific mutations associated with the disease. This approach allows for precise and accurate diagnosis, enabling healthcare professionals to determine the presence of sickle cell trait or SCD in individuals. Additionally, technological advancements have led to the development of point-of-care testing devices, enabling rapid screening and diagnosis in resource-limited settings. These advancements in diagnostic techniques not only enhance early detection and intervention but also facilitate genetic counseling and family planning for individuals at risk of passing on the disease.

Advancements in therapy for hemoglobinopathies, including SCD and thalassemia, have shown promising trends in recent years. Development and utilization of gene therapy approaches is one of the prevalent trend in the market. Gene therapy aims to correct the genetic mutations responsible for these conditions by introducing functional genes into affected cells. Several successful clinical trials have demonstrated significant improvements in disease symptoms and reduced transfusion dependence in patients. Additionally, the emergence of gene editing techniques, such as CRISPR-Cas9, holds great potential for precisely modifying faulty genes in a patient's own cells. This innovative approach has shown promising results in preclinical studies and may offer a curative option for hemoglobinopathies in the near future. Furthermore, advancements in supportive care, including transfusion protocols, iron chelation therapy, and improved stem cell transplantation techniques, continue to contribute to enhanced outcomes for patients with hemoglobinopathies.

An increase in investment and funding for the development of novel therapies to treat hemoglobinopathies will further boost the market growth over the forecast period. For instance, in May 2023, U.S. Senators introduced the Sickle Cell Care Expansion Act, legislation to offer funding for services to advance the quality of life for the growing number of patients living with Sickle Cell and support the medical staff that treats sickle cell disease. Furthermore, private funding such as the Bronx Blood Research Fund (BBRF) provides a platform for research and management of thalassemia and other hemoglobinopathies.

High cost of treatment might an adverse impact on the market. For instance, according to new research supported by the National Institutes of Health, living with sickle cell disease costs Americans ages 64 and under with commercial health insurance about USD 44,000 more in out-of-pocket medical expenses over their lifetimes than people without the condition. Additionally, insurers shell out an average of USD 1.7 million for each sickle cell disease patient.

Hemoglobinopathies Market Report Highlights:

  • The sickle cell disease segment held the largest share of 58.6% in 2022 of the hemoglobinopathies market and is expected to grow at the fastest rate during the forecast period. This is attributed to growing initiatives by biopharmaceutical companies and nonprofit organizations focused on improving access to SCD treatment
  • The sickle cell disease diagnosis segment dominated the hemoglobinopathies market and accounted for a 50.5% share in 2022 owing to high diagnostic rates in North America and Europe
  • By therapy, the sickle cell disease segment held the largest revenue share of 62.1% in 2022. Extensive research coupled with government funding for the development of novel therapies for treating the disorder is the major factor contributing to the segment growth
  • North America held the largest revenue share of 37.7% in 2022 owing to increasing awareness of hemoglobinopathies, improving healthcare facilities and launch of new products in the region are the major factor augmenting the regional growth
  • Asia Pacific is estimated to exhibit the fastest growth rate over the forecast period. The presence of a large number of patients suffering from sickle cell disease and thalassemia is expected to propel market growth in the coming years
  • Major players in the market are Sangamo Therapeutics, bluebird bio, Inc., Global Blood Therapeutics, Inc., Pfizer, Inc., Emmaus Life Sciences, Inc., Prolong Pharmaceuticals, LLC, Celgene Corporation, Bioverativ Inc., Gamida Cell and Novartis AG

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type segment
      • 1.1.1.2. Diagnosis segment
      • 1.1.1.3. Therapy segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type Snapshot
  • 2.3. Diagnosis and Therapy Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of hemoglobinopathies in under - developed countries
      • 3.2.1.2. High unmet needs
      • 3.2.1.3. Increasing R&D investments
      • 3.2.1.4. Initiatives to improve disease awareness levels
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of healthcare infrastructure
      • 3.2.2.2. High cost of treatment
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID - 19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Hemoglobinopathies Market: Type Movement Analysis
  • 4.2. Thalassemia
    • 4.2.1. Thalassemia Market, 2018 - 2030 (USD Million)
  • 4.3. Sickle Cell Disease
    • 4.3.1. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 4.4. Hb Variants
    • 4.4.1. Hb Variants Market, 2018 - 2030 (USD Million)

Chapter 5. Diagnosis Business Analysis

  • 5.1. Hemoglobinopathies Market: Diagnosis Movement Analysis
  • 5.2. Thalassemia
    • 5.2.1. Thalassemia Market, 2018 - 2030 (USD Million)
  • 5.3. Sickle Cell Disease
    • 5.3.1. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 5.4. Hb Variants
    • 5.4.1. Hb Variants Market, 2018 - 2030 (USD Million)

Chapter 6. Therapy Business Analysis

  • 6.1. Hemoglobinopathies Market: Therapy Movement Analysis
  • 6.2. Thalassemia
    • 6.2.1. Thalassemia Market, 2018 - 2030 (USD Million)
  • 6.3. Sickle Cell Disease
    • 6.3.1. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4. Other Hb Variants
    • 6.4.1. Other Hb Variants Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Hemoglobinopathies Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. SWOT Analysis
    • 7.2.2. North America Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.2.3. U.S.
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. U.S. Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.2.4. Canada
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Target Disease Prevalence
      • 7.2.4.3. Competitive Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Canada Hemoglobinopathies Market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. UK Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Germany Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. France Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Italy Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Spain Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Denmark Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Sweden Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Norway Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.3.10. Russia
      • 7.3.10.1. Key Country Dynamics
      • 7.3.10.2. Target Disease Prevalence
      • 7.3.10.3. Competitive Scenario
      • 7.3.10.4. Regulatory Framework
      • 7.3.10.5. Russia Hemoglobinopathies Market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Japan Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. China Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. India Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Australia Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.6. Thailand
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Thailand Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.7. South Korea
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. South Korea Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.4.8. Singapore
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Target Disease Prevalence
      • 7.4.8.3. Competitive Scenario
      • 7.4.8.4. Regulatory Framework
      • 7.4.8.5. Singapore Hemoglobinopathies Market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Brazil Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Mexico Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Argentina Hemoglobinopathies Market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. South Africa Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Saudi Arabia Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. UAE Hemoglobinopathies Market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Kuwait Hemoglobinopathies Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Categorization
    • 8.1.1. Sangamo Therapeutics
      • 8.1.1.1. Overview
      • 8.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.1.3. Product Benchmarking
      • 8.1.1.4. Strategic Initiatives
    • 8.1.2. Bluebird bio, Inc.
      • 8.1.2.1. Overview
      • 8.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.2.3. Product Benchmarking
      • 8.1.2.4. Strategic Initiatives
    • 8.1.3. Global Blood Therapeutics, Inc
      • 8.1.3.1. Overview
      • 8.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.3.3. Product Benchmarking
      • 8.1.3.4. Strategic Initiatives
    • 8.1.4. Pfizer, Inc.
      • 8.1.4.1. Overview
      • 8.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.4.3. Product Benchmarking
      • 8.1.4.4. Strategic Initiatives
    • 8.1.5. Emmaus Life Sciences, Inc.
      • 8.1.5.1. Overview
      • 8.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.5.3. Product Benchmarking
      • 8.1.5.4. Strategic Initiatives
    • 8.1.6. Prolong Pharmaceuticals, LLC
      • 8.1.6.1. Overview
      • 8.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.6.3. Product Benchmarking
      • 8.1.6.4. Strategic Initiatives
    • 8.1.7. Celgene Corporation (BMS)
      • 8.1.7.1. Overview
      • 8.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.7.3. Product Benchmarking
      • 8.1.7.4. Strategic Initiatives
    • 8.1.8. Bioverativ, Inc. (Sanofi)
      • 8.1.8.1. Overview
      • 8.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.8.3. Product Benchmarking
      • 8.1.8.4. Strategic Initiatives
    • 8.1.9. Gamida Cell
      • 8.1.9.1. Overview
      • 8.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.9.3. Product Benchmarking
      • 8.1.9.4. Strategic Initiatives
    • 8.1.10. Novartis AG
      • 8.1.10.1. Overview
      • 8.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 8.1.10.3. Product Benchmarking
      • 8.1.10.4. Strategic Initiatives
  • 8.2. Participant's Overview
  • 8.3. Financial Performance
  • 8.4. Product Benchmarking
  • 8.5. Company Market Share Analysis, 2022
  • 8.6. Strategy Mapping
    • 8.6.1. Expansion
    • 8.6.2. Acquisition
    • 8.6.3. Product/Service Launch
    • 8.6.4. Others

Chapter 9. Analyst View

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 4 Global hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 5 Global hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 6 Global hemoglobinopathies market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 9 North America hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 10 North America hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 11 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 12 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 13 U.S. hemoglobinopathies Market, by therapy, 2018 - 2030 (USD Million)
  • Table 14 Canada hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 15 Canada hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 16 Canada hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 17 Europe hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 18 Europe hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 19 Europe hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 20 Europe hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 21 UK hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 22 UK hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 23 UK hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 24 Germany hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 25 Germany hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 26 Germany hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 27 France hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 28 France hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 29 France hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 30 Italy hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 31 Italy hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 32 Italy hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 33 Spain hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 34 Spain hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 35 Spain hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 36 Denmark hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 37 Denmark hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 38 Denmark hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 39 Sweden hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 40 Sweden hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 41 Sweden hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 42 Norway hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 43 Norway hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 44 Norway hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 49 Japan hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 50 Japan hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 51 Japan hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 52 China hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 53 China hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 54 China hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 55 India hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 56 India hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 57 India hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 58 South Korea hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 59 South Korea hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 60 South Korea hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 61 Australia hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 62 Australia hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 63 Australia hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 64 Singapore hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 65 Singapore hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 66 Singapore hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 67 Thailand hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 68 Thailand hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 69 Thailand hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 70 Latin America hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 72 Latin America hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 73 Latin America hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 74 Brazil hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 75 Brazil hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 76 Brazil hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 77 Mexico hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 78 Mexico hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 79 Mexico hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 80 Argentina hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 81 Argentina hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 82 Argentina hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 86 Middle East & Africa hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 87 South Africa hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 88 South Africa hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 89 South Africa hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 90 UAE hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 91 UAE hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 92 UAE hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 93 Saudi Arabia hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 94 Saudi Arabia hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 95 Saudi Arabia hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 96 Kuwait hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
  • Table 97 Kuwait hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
  • Table 98 Kuwait hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
  • Table 99 Company Overview
  • Table 100 Financial Performance
  • Table 101 Product Benchmarking
  • Table 102 Strategic Initiatives

List of Figures

  • Fig. 1 Hemoglobinopathies market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain - based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hemoglobinopathies market segmentation
  • Fig. 9 Market snapshot, 2022
  • Fig. 10 Market trends & outlook
  • Fig. 11 Market driver relevance analysis (current & future impact)
  • Fig. 12 Market restraint relevance analysis (current & future impact)
  • Fig. 13 PESTEL analysis
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 Global Hemoglobinopathies market: Type movement analysis
  • Fig. 16 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
  • Fig. 17 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
  • Fig. 18 Global Hemoglobinopathies market, for Hb variants, 2018 - 2030 (USD Million)
  • Fig. 19 Global Hemoglobinopathies market: Diagnosis movement analysis
  • Fig. 20 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
  • Fig. 21 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
  • Fig. 22 Global Hemoglobinopathies market, for Hb variants, 2018 - 2030 (USD Million)
  • Fig. 23 Global Hemoglobinopathies market: Therapy movement analysis
  • Fig. 24 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
  • Fig. 25 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
  • Fig. 26 Global Hemoglobinopathies market, for other Hb variants, 2018 - 2030 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Regional outlook, 2022 & 2030
  • Fig. 29 Global Hemoglobinopathies market: Region movement analysis
  • Fig. 30 North America Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 35 UK Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 36 France Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 44 China Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 45 India Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 49 Singapore Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 55 South Africa Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 56 Saudi Arabia Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 57 UAE Hemoglobinopathies market, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait Hemoglobinopathies market, 2018 - 2030 (USD Million)